Summary. The aim of the study was to evaluate efficacy and safety of Iprafen (Ipratropium bromide + fenoterol) and Ipraspir (Ipratropium bromide). Iprafen was used to relieve symptoms of acute bronchial obstruction (wheezing) in comparison with Berodual H in patients with mild–to–moderate persist–ent partially controlled asthma. Ipraspir was used as an adjuvant bronchodilator to relieve cough in comparison with Atrovent H in patients with cough and mild persistent partially controlled asthma. Each group allocated for treatment with Iprafen, Berodual H, Ipraspir or Atrovent H involved 30 asthma patients. In all patients, asthma course was stable during the total study period. There were no difference in reduction of cough attacks between patients treated with Berodual H and Iprafen. Additional administration of Atrovent or Ipraspir resulted in nonsignificant reduction in cough frequency and intensity. In both Ipraspir and Atrovent H groups, the need in short–acting β2–agonists was decreased. Functional parameters did not differed significantly between Iprafen and Berodual H, Ipraspir and Atrovent H groups. Safety of Iprafen and Ipraspir was similar as of Berodual H and Atrovent H, respectively. Therefore, the study showed equal therapeutic efficacy and safety of the drugs.
array г чучалин合作论文数4array н авдеев合作论文数2array р айсанов合作论文数2array н мещерякова合作论文数2array м ненашева合作论文数2array п княжеская合作论文数2array в лещенко合作论文数1array а кузубова合作论文数1А. Ф. Абубикиров合作论文数1array н титова合作论文数1array к волков合作论文数1array ю бушманов合作论文数1array а кронина合作论文数1array м кочеткова合作论文数1array и чарикова合作论文数1array е волкова合作论文数1array в бердзенадзе合作论文数1array н чуприна合作论文数1array м матишева合作论文数1array а тихоход合作论文数1array н отс合作论文数1array и чушкин合作论文数1array ревякина合作论文数1array г шуганов合作论文数1array а карнаушкина合作论文数1array а геппе合作论文数1
